Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 studyXinxin Cao, Daobin Zhou, Jianda Hu et al.|EClinicalMedicine|2022Cited by 43
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Xin Du, Hui Zhou et al.|Advances in Therapy|2021Cited by 19
Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia PatientsDaobin Zhou, Xiangyang Zhang, Jie Jin et al.|Blood|2021Cited by 11
Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up ResultsXinxin Cao, Daobin Zhou, Jie Jin et al.|Blood|2023Cited by 4